The Role of Nitisinone in Tyrosine Pathway Disorders

Current Rheumatology Reports

Volumn 16, Issue 11, 2014, Pages

  Lock, Edward ^a   Ranganath, Lakshminarayan R ^b   Timmis, Oliver ^c  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c AKU Society   (United Kingdom)

Author keywords

4 hydroxyphenylpyruvate dioxygenase; Alkaptonuria; Clinical research; Clinical trial; Homogentisic acid; Metabolomics; Nitisinone; Rare disease; Tyrosinaemia type 1

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; HOMOGENTISATE 1,2 DIOXYGENASE; NITISINONE; CYCLOHEXANONE DERIVATIVE; ENZYME INHIBITOR; NITROBENZOIC ACID DERIVATIVE;

ALKAPTONURIA; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; INCIDENCE; KERATOPATHY; MORBIDITY; NONHUMAN; RASH; REVIEW; TREATMENT OUTCOME; TYROSINEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; MEDICAL RESEARCH; OFF LABEL DRUG USE; TYROSINEMIAS;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ALKAPTONURIA; ANIMALS; BIOMEDICAL RESEARCH; CYCLOHEXANONES; ENZYME INHIBITORS; HUMANS; NITROBENZOATES; OFF-LABEL USE; TYROSINEMIAS;

EID: 84920885080     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0457-0     Document Type: Review

References (38)

1. Garrod AE. The Croonian lectures on inborn errors of metabolism. Lecture II. Alkaptonuria. Lancet. 1908;2:73–9.
2. Michaely WJ, Kratz GW. Certain 2-(2-substituted benzoyl)-1,3-cyclohexanediones. 1986; European Patent Application 0135191.
3. Beaudegnies R, Edmunds AJF, Frazer TEM, et al. Herbicidal 4-hydroxyphenylpyruvate dioxygenase inhibitors – a review of the triketone chemistry story from a Syngenta perspective. Bioorg Med Chem. 2009;17:4134–52.
4. Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol. 1996;141:439–47.
5. Lock EA, Gaskin P, Ellis MK, et al. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury. Toxicol Appl Pharmacol. 2006;215:9–16.
6. Robinson M. The corneal effects of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in the rat. In: Weisse I, Hockwin O, Green K, Tripathi RC, editors. Ocular toxicology. New York and London: Plenum Press; 1995. p. 327–34.
7. Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology. 2000;144:179–87.
8. Koizumi S, Nagatsu T, Iinuma H, et al. Inhibition of phenyl hydroxylase, a pterin-requiring monooxygenase by oudenone and its derivatives. J Antibiot. 1982;35:458–62.
9. Prisbylla MP, Onisko BC, Shribbs JM, et al. The novel mechanism of action of the herbicidal triketones. Weeds. 1993;3:731–8.
10. Lindstedt S, Odelhog B. 4-Hydroxyphenylpyruvate dioxygenase from human liver. Methods Enzymol. 1987;142:139–42.
11. Moran GR. 4-Hydroxyphenylpyruvate dioxygenase. 2005;433:117-28.
12. Ellis MK, Whitfield AC, Gowan LA, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulphonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl Pharmacol. 1995;133:12–9.
13. Lock EA, Gaskin P, Ellis MK, et al. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinaemia, and the activity of enzymes involved in tyrosine catabolism in the rat. Toxicol Appl Pharmacol. 1998;150:125–32.
14. Rich LF, Beard ME, Burns RP. Excess dietary tyrosine and corneal lesions. Exp Eye Res. 1973;17:87–97.
15. Goldsmith LA, Laberge C. Tyrosinaemia and related disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill; 1989. p. 547–62.
16. DeBraekeller M, Larochelle J. Genetic epidemiology of hereditary tyrosinaemia in Quebec and Saguenay-Lac-St- Jean. Am J Hum Genet. 1990;47:302–7.
17. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813–7.
18. Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab. 2012;107:49–54. A recent review on the efficacy of nitisinone for the treatment of HT-1.
19. Bodeker. Zeitschrift fur Rationale Medicin. 1859;VII:130.
20. Wolkow, Baumann. Z Physiol Chem. 1891;XV:228.
21. La Du BN, Zannoni VG, Laster L, et al. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem. 1958;230:251–60.
22. Pollak MR, Chou YH, Cerda JJ, et al. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet. 1993;5:201–4.
23. O’Brien WM, La Du BN, Bunim JJ. Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: review of world literature (1584–1962). Am J Med. 1963;34:813–38.
24. Introne WJ, Phornphutkul C, Bernardini I, et al. Exacerbation of the ochronosis of Alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002;77:136–42.
25. Zannoni VG, Lomtevas N, Goldfiner S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta. 1969;177:94.
26. Helliwell TR, Gallagher JA, Ranganath LR. Alkaptonuria – a review of surgical and autopsy pathology. Histopathology. 2008;53:503–12.
27. Zibolen M, Srsnova K, Srsen S. Increased urolithiasis in patients with alkaptonuria in childhood. Clin Genet. 2000;58:79–80.
28. Ranganath LR, Cox TF. Natural history of Alkaptonuria revisited: analyses based on scoring systems. J Inherit Metab Dis. 2011;34:1141–51. A recent review describing the natural history of AKU.
29. Krizek V. Urolithiasis and prostatolithiasis in alcaptonuria with ochronosis. Int Urol Nephrol. 1971;3:245–50.
30. Manoj Kumar RV, Rajasekaran S. Spontaneous tendon ruptures in Alkaptonuria. J Bone Joint Surg Br. 2003;85:883–6.
31. Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. 2004;2:209–15.
32. Akeda K, Kasai Y, Kawakita E, et al. Thoracic myelopathy with Alkaptonuria. Spine. 2008;33:E62–5.
33. Taylor AM, Boyde A, Wilson PJ, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum. 2011;63:3887–96. A recent review describing the process of AKU damage to cartilage.
34. Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in Alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res. 1989;26:140–4.
35. Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article) [Review]. J Clin Pathol. 2013;66:367–73. A recent review detailing current best practise for the clinical management of alkaptonuria.
36. Laxon S, Ranganath L, Timmis O. A patient’s journey: living with Alkaptonuria. Br Med J. 2011;343:d5155.
37. Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in Alkaptonuria. Mol Genet Metab. 2011;103:307–14.
38. Stewart RM, Briggs MC, Jarvis JC, et al. Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report. JIMD Rep. 2014.